MiR-362-5p promotes the malignancy of chronic myelocytic leukaemia via down-regulation of GADD45α by Peng Yang et al.
RESEARCH Open Access
MiR-362-5p promotes the malignancy of
chronic myelocytic leukaemia via down-
regulation of GADD45α
Peng Yang1,2†, Fang Ni1†, Rui-qing Deng1, Guo Qiang1, Hua Zhao1, Ming-zhen Yang3, Xin-yi Wang1,4, You-zhi Xu1,
Li Chen1, Dan-lei Chen1, Zhi-jun Chen1, Li-xin Kan1 and Si-Ying Wang1*
Abstract
Background: MicroRNAs (miR, miRNAs) play pivotal roles in numerous physiological and pathophysiological
contexts. We investigated whether miR-362-5p act as an oncogene in chronic myeloid leukaemia (CML) and aimed
to understand its potential underlying mechanisms.
Methods: We compared the miR-362-5p expression levels between CML and non-CML cell lines, and between
fresh blood samples from CML patients and normal healthy controls using quantitative real-time PCR (qPCR). Cell
counting kit-8 (CCK-8) and Annexin V-FITC/PI analyses were used to measure the effects of miR-362-5p on
proliferation and apoptosis, and Transwell assays were used to evaluate migration and invasion. A xenograft model
was used to examine in vivo tumourigenicity. The potential target of miR-362-5p was confirmed by a luciferase
reporter assay, qPCR and western blotting. Involvement of the JNK1/2 and P38 pathways was investigated by
western blotting.
Results: miR-362-5p was up-regulated in CML cell lines and fresh blood samples from CML patients, and was
associated with Growth arrest and DNA damage-inducible (GADD)45α down-regulation. Inhibition of miR-362-5p
simultaneously repressed tumour growth and up-regulated GADD45α expression in a xenograft model. Consistently,
the knockdown of GADD45α expression partially neutralized the effects of miR-362-5p inhibition. Furthermore study
suggested that GADD45α mediated downstream the effects of miR-362-5p, which might indirectly regulates the
activation of the JNK1/2 and P38 signalling pathways.
Conclusion: miR-362-5p acts as an oncomiR that down-regulates GADD45α, which consequently activates the
JNK1/2 and P38 signalling. This finding provides novel insights into CML leukaemogenesis and may help
identify new diagnostic and therapeutic targets.
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Background
Chronic myeloid leukemia (CML) is a relatively common
malignant hematopoietic disorder (~1-2 cases /100,000/
year). CML accounts for approximately 15 % of leukae-
mia case in adults [1, 2], and it is consistently associated
with a reciprocal translocation of 9q34 with 22q11,
which generates the Breakpoint cluster region/ Abelson
oncogene (BCR/ABL) fusion gene that is translated into
an oncoprotein (P210BCR/ABL) [2–4]. The P210BCR/ABL
oncoprotein is a constitutively active tyrosine kinase that
leads to uncontrolled cell growth and the malignant
expansion of myeloid cells in the bone marrow and per-
ipheral blood [2, 5, 6]. Small molecule tyrosine kinase
inhibitors (TKIs) that directly suppress BCR-ABL activity
are currently used to treat of CML [7, 8]; however,
resistance and intolerance to TKIs prevent a full thera-
peutic benefit in 20 -30 % of patients [1, 9]. In addition,
side-effects, such as diarrohea, skin toxicity and allergic
reaction remain serious clinical problems [10]. Therefore,
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a better understanding of the tumour biology of CML and
alternative therapeutic avenues are urgently needed.
MicroRNAs (miRNAs, miR) are endogenous and
highly conserved RNAs that normally base-pair with the
3’-untranslated region (UTR) of protein-encoding mes-
senger RNA (mRNA), and suppress protein expression
by inhibiting the translation and/or cleavage of target
mRNAs [11, 12]. miRNAs play key roles in numerous
biological processes, including cell growth, cell cycle
progression, apoptosis, migration and invasion [13].
Dysregulated miRNAs may act as oncogenes or
tumour suppressors, depending on the biological
function of their targets [14, 15]. For example, miR-
370 reduces leukaemogenesis in acute lymphoblatic
leukaemia (ALL) and CML by targeting the oncogene
FoxM1 [16, 17], whereas miR-451 is known to targets
TSC1 and GRSF1 in CML [18], and miR-196b targets
HOXA in paediatric acute ALL [19]. miR-362-5p was
first reported by Bentwich and colleagues in primate
testes [20]. Our prior work has shown that miR-362-5p
promotes hepatocellular carcinoma growth and metastasis
by targeting CYLD [21]. However, the biological role and
underlying mechanisms of miR-362-5p in CML have not
been investigated.
Growth arrest and DNA damage-inducible (GADD)45α
was originally identified as a tumour suppressor of
multiple types of solid tumors and hematopoietic ma-
lignancies, and it was also implicated in stress signal-
ling [22, 23]. GADD45α is involved in proliferation,
apoptosis, cell cycle control, and nucleotide excision
repair [24, 25]. Recent studies have shown that
GADD45α expression is frequently down-regulated in
CML, and down-regulation of GADD45α induces
tumour cell proliferation, leukaemogenesis and CML
progression [26–29]. Nevertheless, the molecular
mechanism underlying dsyregulated GADD45α ex-
pression remains unknown.
GADD45α has been shown to play a predominant role
in the regulation of c-Jun N-terminal kinase (JNK) and
P38 mitogen-activated protein kinase (MAPK) signalling.
Specifically, JNK and P38 MAPK are implicated in CML
development and progression [30, 31]. These two
pathways are frequently found to be inactivated in
CML. Conversely, the activation of P38 MAPK and
JNK are generally implicated in the suppression of
leukaemogenesis [31–33].
In this study, we investigated whether miR-362-5p is
an oncogene in CML and aimed to further understand
the potential underlying mechanisms of its action in
vitro and in vivo. This study reveals a novel role of
miR-362-5p in CML tumourigenesis and progression,
and we partially delineated the underlying molecular
mechanism, providing novel insights into the tumour
biology of CML.
Results
miR-362-5p is highly expressed in both leukaemia cell
lines and fresh CML samples
To test the expression and significance of miR-362-5p in
leukaemia, quantitative real-time PCR (qPCR) was used
to measure the expression levels of miR-362-5p in sev-
eral leukaemia cell lines. Specifically, we found that miR-
362-5p was highly expressed in leukaemia cell lines, such
as BV173, K562, Ball-1 and Jurkat, but it not in non-
leukemia 293 T cells and normal CD34+ cells (Fig. 1a);
and the highest level of miR-362-5p expression was
found in CML cell lines (BV173 and K562, Fig. 1a).
Therefore, we selected CML patients as our research
subjects in further studies. We found that the levels of
miR-362-5p at the time of diagnosis in 40 fresh CML
peripheral blood samples were significantly higher than
those of 26 healthy controls (Fig. 1b). More importantly,
miR-362-5p was down-regulated in 8 CML patients after
TKIs induced complete hematologic response (Fig. 1c).
Furthermore, the inhibition of BCR-ABL activity by
treatment with 1 μM imatinib significantly suppressed
miR-362-5p expression levels in K562 cells (Fig. 1d). We
next explored the miR-362-5p expression levels in ima-
tinib-resistant leukaemic cells. miR-362-5p expression in
imatinib-resistant K562 cells (K562IR) was approximately
4.2-fold higher than that in imatinib-sensitive K562 cells
(Additional file 1). These results support the idea that
miR-362-5p might play oncogenic role in CML.
Reduction of cell growth and induction of cell apoptosis
by suppression of miR-362-5p
To further analyse the function of miR-362-5p in CML,
cell growth was first detected in BV173 and K562 cells
using a gain-of-function approach. BV173 and K562 cells
were transfected with a miR-362-5p mimic. Successful
increases in miR-362-5p expression were measured
using qRT-PCR (Additional file 2A). Our results showed
that overexpression of miR-362-5p increased the growth
of the BV173 and K562 cells (Additional file 2B and 3).
We then tested the effects of miR-362-5p loss-of-
function on CML proliferation. Specially, BV173 and
K562 cells were transfected with a specific inhibitor of
miR-362-5p or a negative control. As expected, success-
ful inhibition of mature miR-362-5p in these cells was
detected by qRT-PCR (Fig. 2a). A Cell counting kit-8
(CCK-8) proliferation assay showed that cell growth was
suppressed in cells transfected with the miR-362-5p in-
hibitor, compared with cells transfected with a negative
control or untreated cells (Fig. 2b). Accordingly, miR-
362-5p suppression in both BV173 and K562 cells
triggered cell cycle arrest in the G1 phase and a re-
duction in the number of cells in S phase (Fig. 2c).
Next, we used Annexin V-FITC/PI staining to test
whether miR-362-5p suppression induce cell apoptosis.
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We found that miR-362-5p suppression induced cell
apoptosis at 48 h in both K562 and BV173 cells (Fig. 2d).
Furthermore, we tested whether the miR-362-5p inhibi-
tor could further enhance the pro-apoptotic effects of
cytosine arabinoside (Ara-c, 5 μg/ml), a common syner-
gistic drug to treat CML [34]. In this experiment, K562
and BV173 cells were transfected with a miR-362-5p in-
hibitor or a negative control. Twenty-four hours after
transfection, the cells were treated with or not Ara-c for
24 h, miR-362-5p suppression enhanced apoptosis in-
duced by Ara-c treatment (Fig. 2d).
Knockdown of miR-362-5p inhibits the migration and
invasion of BV173 and K562 cells
To further assess whether miR-362-5p is associated with
extramedullary infiltration progression during CML, we
analysed the effect of miR-362-5p expression on the
migratory and invasive behaviour of K562 and BV173
cells, using a Transwell/Matrigel assay. We found that
mobility and invasiveness were dramatically reduced
in miR-362-5p inhibitor transfected BV173 and K562
cells in vitro, compared with their corresponding
negative controls or untreated cells (Fig. 3a and b).
Inhibition of miR-362-5p suppresses tumour growth in a
xenograft model
The high level of miR-362-5p expression in CML cell
lines and patient samples prompted us to assess the role
of miR-362-5p in tumorigenesis. Colony formation
assays were performed to evaluate the growth capacity
of CML cell lines (K562 and BV173) transfected with a
specific inhibitor of miR-362-5p or a negative control.
As expected, miR-362-5p inhibitor transfected cells dis-
played fewer and smaller colonies, than did the negative
control cells (Additional file 4).
To better understand the role of miR-362-5p in
tumorigenesis in vivo, we constructed a lentiviral plas-
mid that expressed a miR-362-5p inhibitor or control,
and then established stable K562 cell lines with these
lentiviruses. The expression of miR-362-5p was verified
by qRT-PCR (Additional file 5). The stable cell lines
were subsequently inoculated subcutaneously into the
left subaxillary region of nude mice, and miR-362-5p ex-
pression levels in these tumours were measured. In the
miR-362-5p inhibitor group, miR-362-5p expression was
indeed reduced (P < 0.01) compared with the control
group (Additional file 6). In agreement with the in vitro
cell growth results, tumour growth was remarkably
Fig. 1 MiR-362-5p was up-regulated in leukaemia cell lines and most of the fresh specimens from CML patients; however, this up-regulation could
be inhibited, if the CML were in complete hematologic response induced by imatinib. MiR-362-5p was detected by qRT-PCR in the following samples:
(a) 4 leukemia cell lines, CD34+ cells and 293Tcells. b 40 CML specimens and 26 normal individual. c Samples from 8 CML patients prior to treatment
(at diagnosis time) and after complete hematologic response. d K562 cell line treated with1 μM imatinib. U6 small nuclear RNA gene (U6snRNA) was
used as an internal control. Data are shown as mean ± SD. t test,*P < 0.05, ** P <0.01 compare with CD34+ (a), normal (b), untreated (c and d)
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Fig. 2 Inhibition of miR-362-5p suppresseed cell proliferation, induced cell apoptosis and cell cycle arrests during G1 phase, in both BV173 and K562 cells.
BV173 and K562 cells were either left untransfected or were transfected with either a miR-362-5p inhibitor (inhibitor) or a miR-362-5p inhibitor control
(inhibitor-ctrl). a Relative expression of miR-362-5p was analysed by qRT-PCR. U6snRNA was used as an internal control. b Proliferation of BV173 and K562
cells was using the CCK-8 assay. c CML cell lines were stained with PI. The cell cycle distribution was analysed by FACS. d CML cell lines (in the absence
or presence of 5 μg/ml Ara-c) were stained with PI and Annexin V. Early and late apoptotic cells are shown in the right quadrant. *P < 0.05,**P < 0.01
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slower in the miR-362-5p inhibitor group than in the
control group (Fig. 4a-c). These data suggest that the
knockdown of miR-362-5p markedly inhibits the
tumourigenicity of K562 cells. Because GADD45α is con-
sidered a tumour suppressor of BCR-ABL driven leukae-
mia [27, 35], we measured the expression of GADD45α by
immunohistochemistry in the neoplasm tissue extracted
from miR-362-5p inhibitor and control mice. Interestingly,
the neoplasm from miR-362-5p inhibitor mice expressed
higher levels of GADD45α than the controls (Fig. 4d).
GADD45α is a direct target of miR-362-5p
We next examined the effect of miR-362-5p on
GADD45α expression. We transfected the miR-362-5p
mimic into 293 T cells, which endogenously express low
levels of miR-362-5p (Fig. 1a). qRT-PCR confirmed in-
creased miR-362-5p expression in 293 T cells (Additional
file 7). The overexpression of miR-362- 5p dramatically
down-regulated GADD45α mRNA levels (Fig. 5a, left).
Conversely, knockdown of miR-362-5p increased the
mRNA levels of GADD45α in both K562 and BV173 cells
(Fig. 5a, right), which endogenously express high levels of
miR-362-5p (Fig. 1a).
Furthermore, GADD45α protein levels were mark-
edly reduced in 293 T cells after transfection with the
miR-362-5p mimic (Fig. 5b, left), and the suppression
of the expression of miR-362-5p by an miR-362-5p
inhibitor substantially increased the GADD45α protein
levels in both BV173 and K562 cells (Fig. 5b, middle,
right). Consistent with these results, lower GADD45α
protein levels were observed (Fig. 5c) in cell lines that
endogenously expressed higher levels of miR-362-5p
(Ball-1, Jurkat, BV173 and K562, Fig. 1a), whereas the
opposite was true for cell lines expressing lower levels of
miR-362-5p (293 T, CD34+, Fig. 1a). Similarly, protein
levels of GADD45α in CML patients were lower than
those in healthy control (Fig. 5d).
Based on these data, we reasoned that GADD45α
might be a downstream target of miR-362-5p. In support
of this idea, a complementary site of miR-362-5p was
identified in the 3’-UTR of GADD45α mRNA. Further-
more, the 3’-UTR of GADD45α mRNA is highly conserved
among various mammals (Fig. 5e, left). Nevertheless, to
directly test this hypothesis, GADD45α wild- type/mutant
3’-UTRs containing the putative miR-362-5p binding sites
were cloned into the psi-CHECK2 reporter vector
downstream of the Photinus pyralis/Renila reniformis
dual luciferase reporter gene (Fig. 5e, left). 293 T cells
co-transfected with the wild-type 3’-UTR reporter
vector and the miR-362-5p mimic showed a significant
Fig. 3 Inhibition of miR-362-5p suppressed the migration and invasion of CML cell lines. a, b Left panel: Transwell assays were performed to
evaluate the migratory and invasive capabilities of the cells untransfected, transfected with either a miR-362-5p inhibitor (inhibitor) or a miR-362-5p
inhibitor control (inhibitor-ctrl). Right panel: Quantitative analysis of the migration and invasion rates. ** P <0.01
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reduction in luciferase activity, whereas the luciferase ac-
tivity in the cells transfected with the mutant-type 3’-UTR
vector was unaffected by the miR-362-5p mimic (Fig. 5e,
middle). Because K562 and BV173 cells endogenously
express high levels of miR-362-5p (Fig. 1a), we co-
transfected the miR-362-5p inhibitor and wild-type 3’-
UTR reporter vector into these cells, which demonstrated
the luciferase activity was significantly increased in the
presence of the miR-362-5p inhibitor (Fig. 5e, right).
Taken together, these data provide evidence that
GADD45α is a direct target of miR-362-5p and that its
expression is negatively regulated by miR-362-5p.
Fig. 4 Inhibition of miR-362-5p suppressed tumour growth in nude mice. K562 cells infected with lentivirus expressing either miR-362-5p inhibitor
(lv-inhibitor) or miR-362-5p inhibitor control (lv-ctrl) were subcutaneously injected into the left axilla of nude mice. a Tumour growth curves were
determined by measuring tumor volumes on the indicated days. b & c The graphs are the representative images of the mice (b) and tumours
isolated 3 weeks after inoculation. Tumour volumes and weights were calculated. d Expression of GADD45α was analysed by immunohistochemistry
in the tissues extracted from nude mice. Data are shown as mean ± SD, **P < 0.05, **P < 0.01
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Fig. 5 (See legend on next page.)
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Alterations of GADD45α expression levels influence the
effects of miR-362-5p on CML cells
To further confirm that GADD45α is a functional target
of miR-362-5p, we over-expressed GADD45α by the
transfecting cells with the miR-362-5p inhibitor, or si-
lenced GADD45α by transfecting cells with GADD45α
small interfering RNA (siRNA). As expected, the miR-
362-5p inhibitor increased GADD45α protein levels
(Fig. 5b), and this effect was partially rescued by
GADD45α siRNA (Fig. 6a and b). GADD45α binds the
MEKK4 N-terminus, which activates the P38 and JNK
signalling pathways [36, 37]. Thus, we tested whether
(See figure on previous page.)
Fig. 5 GADD45α is a direct target of miR-362-5p. a The relative expression of GADD45α mRNA was analysed by qRT-PCR, under different contexts,
GAPDH was used as an internal control. Left panel: 293 T cells untransfected or transfected with a mimic control (mimic-ctrl) or a miR-362-5p
mimic (mimic) as indicated. Right panel: BV173 and K562 cells were either left untransfected or were transfected with either a miR-362-5p
inhibitor (inhibitor) or a miR-362-5p inhibitor control (inhibitor-ctrl), as indicated. b The protein expression of GADD45α was measured by
Western blotting under the same conditions. Top panel of (b) shows the typical images of western blotting, and the bottom panel of (b)
shows the respective quantifications. c Expression of GADD45α protein was examined by Western blotting in normal CD34+ cells, 293 T cells
and 4 leukemia cell lines. Protein expression was quantified and normalized to β-actin. d Expression of GADD45α protein was examined by
Western blotting in 3 healthy controls and 6 CML patients. Protein expression was quantified and normalized to β-actin. e Left panel: Sequence of the
miR-362-5p binding sites within the human GADD45α 3’-UTR and a schematic diagram of the reporter constructs showing the wild-type
GADD45α 3’-UTR sequence (wt) and the mutated GADD45α 3’-UTR sequence (mut). Shaded areas represent conserved complementary
nucleotides of the miR-362-5p seed sequence in various mammals (Has: human, ptr: chimpanzee, Mml: rhesus, Mmu :mouse, Rno: rat, and
cfa: dog) Middle panel: Luciferase activity assay in, 293 T cells, with cotransfection of the wt-or-mut-reporter and a miR-362-5p mimic (mimic) or a
miR-362-5p mimic control (mimic-ctrl) as indicated. Right panel: Luciferase activity assay, as above, with an miR-362-5p inhibitor (inhibitor) and an
miR-362-5p inhibitor control (inhibitor-ctrl) in BV173 and K562 cells . **P < 0.01
Fig. 6 MiR-362-5p functioned through GADD45α in inhibiting JNK1/2 and P38 signalling. Western blotting for GADD45α, JNK1/2, p-JNK1/2, P38 and
p-P38 in K562 cells and BV173 cells transfected with inhibitor-control (inhibitor-ctrl) and siGADD45α scrambled oligonucleotide (si-ctrl), inhibitor-ctrl
and siGADD45α, inhibitor and si-ctrl, or inhibitor and siGADD45α. Protein expression was quantified by band intensity and normalized to β-actin. in
K562 cells a. in BV173 cells b. **P < 0.01
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miR-362-5p regulates JNK1/2 and P38 by targeting
GADD45α. We found the inhibition of miR-362-5p sig-
nificantly increased phosphor-JNK1/2 and phosphor-P38
levels in K562 and BV173 cells. Moreover, GADD45α
siRNA (siGADD45α) significantly restored P38 and JNK
activity in miR-362-5p inhibited K562 and BV173 cells
(Fig. 6a and b). These data further support the notion
that GADD45α is a downstream functional mediator of
miR-362-5p.
We next investigated whether miR-362-5p regulates
CML cell function by repressing GADD45α. As ex-
pected, a cell proliferation assay (Fig. 7a) showed that
the inhibition of miR-362-5p significantly decreased the
growth of K562 and BV173 cells. More importantly,
GADD45α siRNA reversed the effects of miR-362-5p in-
hibition on these CML cells (Fig. 7a). A similar
phenomenon was observed in a cell apoptosis assay
(Fig. 7b). Additionally, siGADD45α attenuated miR-362-
5p suppression induced apoptosis in CML cells following
Ara-c treatment (Fig. 7b, lower row). Taken together,
these experimental data suggest that multiple cellular
processes (cell growth, migration and invasion) are regu-
lated by miR-362-5p, and these miR-362-5p functions at
least partially rely on the suppression of GADD45α
expression.
Discussion
In this study, we analysed miR-362-5p expression during
CML, and our data show that miR-362-5p expression is
higher in both CML patient’ samples and cell lines com-
pare to controls. Based on this novel finding, we further
explored the role of this miRNA in CML. Interestingly,
our observations indicate that the down-regulation of
miR-362-5p significantly suppresses CML cell prolifera-
tion, enhances cell apoptosis, induces cell cycle arrest,
and decreases migration and invasion in vitro, whereas a
miR-362-5p inhibitor reduced tumour volume and
tumour growth in vivo in a xenograft model. Furthermore,
we found that miR-362-5p inhibitor increases the sensitiv-
ity of CML cell lines to the chemotherapeutic agent Ara-c.
Taken together, these results indicate that miR-362-5p acts
as a novel oncogenic miRNA (oncomiR) that exerts a
important effects on CML progression.
Further mechanistic studies indicated that GADD45α
may be a key downstream target gene of miR-362-5p.
GADD45α, a P53 target gene, has been identified as a
tumour suppressor [38], because it promotes cell apop-
tosis and inhibits angiogenesis [29, 38, 39]. Indeed,
GADD45α-/- mice display increased mutation frequen-
cies, and increased susceptibility to ionizing radiation and
carcinogens [24, 40]. Recently, GADD45α protein was
shown to act as a sensor of oncogenic stress during the
development of hematopoietic cells. Furthermore, altered
GADD45α expression may play a role in leukaemogenesis
[25, 29], because GADD45α expression is significantly
down-regulated in AML and CML [29, 41]. Previous stud-
ies have revealed that miR-148 suppresses the expression
of GADD45α in lung cancer and that GADD45α is regu-
lated by miR-130b in benign thyroid nodule tumorigenesis
[42, 43]. Thus, multiple miRNAs likely participate in the
regulation of GADD45α expression in different contexts;
however, the ability of miR-362-5p to directly regulate
GADD45α remains unknown.
In this study, we found that GADD45α could be a dir-
ect target of miR-362-5p by the luciferase reporter assay
and quantitative PCR, western blotting with samples
from CML cell lines or patients’ samples further sup-
ports the idea. Knockdown of miR-362-5p inhibited the
proliferation and promoted apoptotic of CML cells,
which were attenuated by the siRNA mediated suppres-
sion of GADD45α. These data suggest that the miR-362-
5p/GADD45α axis could be a key growth regulator of
CML and that miR-362-5p is an oncomiR.
In addition, our data also suggest that miR-362-5p reg-
ulates activation of the P38 and JNK signalling pathways,
likely via GADD45α. Although the mechanisms under-
lying this activation remains poorly understood, previ-
ously obtained data suggested that GADD45α can bind
to the MEKK4 N-terminus. This binding activates the
P38 and JNK signalling pathways via a conformational
change that results in its autophosphorylation, activa-
tion, to strongly induce cell senescence and apoptosis
[36, 37, 44, 45].
Because aberrant miRNA expression appears to be a
characteristic phenotype of many cancers, miRNA ex-
pression profiling likely has potential diagnostic value
[46], and the reintroduction or inhibition miRNA or
inhibiting miRNAs may be a promising therapeutic
approach [46–48]. Indeed, several reports recently con-
firmed the feasibility of using microRNAs as a new
therapeutic tool [49–51]. Here, we propose that down-
regulation of miR-362-5p expression with an miR-362-
5p inhibitor can inhibit the proliferation and enhance
apoptosis of cancer cells. Therefore, therapies targeting
miR-362-5p in combination with existing conventional
therapies may be a novel strategy against CML.
Conclusion
In summary, we have identified for the first time that
the oncomiR miR-362-5p directly targets GADD45a and
indirectly regulates the P38 and JNK signalling pathways
in CML. These findings may have direct implications for
both basic medical research and clinical applications.
Methods
Cell lines and imatinib treatment
Ball-1 and Jurkat cells (human acute leukaemia cell
lines), BV173 and K562 cells (human chronic myeloid
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Fig. 7 Knockdown of GADD45α expression neutralized the effect of the miR-362-5p inhibitor. a Proliferation of BV173 and K562 cells transfected
with inhibitor control (inhibitor-ctrl) and siGADD45α scrambled oligonucleotide (si-ctrl), inhibitor-ctrl and siGADD45α, inhibitor and si-ctrl, or inhibitor
and siGADD45α was determined using the CCK-8 assay at the indicated times. The values represent the means ± SD of three replicates. b BV173 and
K562 cells (in the absence or presence of 5 μg/ml Ara-c) were stained with PI and Annexin V after cotransfection, as described above. Early and late
apoptotic cells are shown in the right quadrant. *P < 0.05,**P < 0.01
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leukaemia cell lines), and 293 T cells (human embryonic
kidney cell line) were purchased from the Shanghai In-
stitute of Cell Biology, Chinese Academy of Sciences
(Shanghai, China). These five cell lines were cultured in
RPMI-1640 media (Gibco, Carlsbad, CA, USA) contain-
ing 10 % heated-inactivated foetal bovine serum (FBS,
Gibco) and 10 U/ml penicillin-streptomycin (Sigma,
USA) in a humidified incubator at 37 °C in 5 % CO2 and
95 % air. Primary CD34+ cells (human normal bone mar-
row CD34+ stem/progenitor cells) were kindly provided
by Doctor Qing-sheng Li (Department of Haematology,
First Affiliated Hospital, Anhui Medical University, Hefei,
China). Imatinib-resistant K562 cells (K562IR) were kindly
provided by Prof. Qiu-ying Huang (Department of
Hematology, Affiliated Hospital, Suzhou university,
Suzhou, China). The K562IR cells were cultured in the
same medium containing 1 μM imatinib (STI571,Gleevec;
Novartis) [52].
BCR-ABL activity in K562 cells was inhibited by treat-
ment with imatinib at a final concentration of 1 μM for
48 h [52]. The cells were then harvested for real-time PCR.
Patients and normal controls
Forty newly diagnosed CML patients and 26 healthy
controls were enrolled in this study (Additional file 8:
Table S1). Approval was obtained from the Medical Eth-
ics and Human Clinical Trial Committee at Anhui Med-
ical University. All patients and healthy volunteers gave
informed consent. Peripheral blood specimens were col-
lected between April 2012 and September 2014 at the
Department of Haematology, First Affiliated Hospital,
Anhui Medical University, Hefei, China. The samples
were immediately snap-frozen or stored at -80 °C. The
samples were prepared with erythrocyte lysis buffer
(Qiagen, Hilden, Germany) according to the manufac-
turer’s protocol prior to RNA extraction and protein
analysis.
Quantitative real time PCR (qRT-PCR)
Total RNA was extracted from cells using TRIzol re-
agent (Invitrogen) following the manufacturer’s protocol.
RNA purity and concentration were determined using a
BioPhotometer (Eppendorf, Germany). Levels of mature
miRNAs were measured using a Hairpin-itTM miRNA
qPCR Quantitation Kit (GenePharma, Shanghai, China)
according to manufacturer’s instructions. The U6 small
nuclear RNA gene (U6 snRNA) served as an internal
control. Relative mRNA levels of GADD45α were quan-
tified using cDNA synthesized from total RNA, and
(glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
served as an internal control). RNA was reverse-
transcribed using RevertAid Moloneymurine leukaemia
virus Reverse transcriptase (Thermo, USA) and random
primers (Thermo). cDNA was then amplified with
specific primers and Power SYBR Green PCR Master
Mix (Applied Biosystems). The sequences of the primer
used are listed in Additional file 8: Table S2.
Transient transfection of miRNA mimic, inhibitor, siRNA
and Ara-c treament
293 T, BV173, and K562 cells were seeded in 6-well or
10-cm dishes. Transient transfections of miR-362-5p
mimic and/or inhibitor, and negative control oligonucle-
otides (mimic-ctrl, or inhibitor-ctrl) (Genepharma,
Shanghai, China) (Additional file 8: Table S3) at a final
concentration of 50 nM were accomplished with Lipo-
fectamine 2000 (Invitrogen, Carlsbad, CA, USA), follow-
ing the manufacturer’s protocol. Similarly, cells were
transiently transfected with siGADD45α and negative
control scramble (si-ctrl) (Genepharma) at a final concen-
tration of 25 nM. Protein assays and qRT-PCR analyses
were conducted 48 h after transfection. Cell apoptosis/cell
cycle were analyzed at 48/72 h after transfection. Soft-agar
colony formation, migration and invasion assays were
performed at 12 h after transfection.
BV173 and K562 cells were either left untransfected or
were transfected with sythetic RNA (inhibitor-ctrl, in-
hibitor, inhibitor-ctrl and si-ctrl, inhibitor-ctrl and
siGADD45α, inhibitor-ctrl and si-ctrl, or inhibitor and
siGADD45α) similar above described. After 24 h, cells
were treated with 5 μg/ml Ara-c (Hisun pharma,
Taizhou, China). Cell apoptosis were analyzed at 24 h
after Ara-c treatment.
Cell proliferation, cell cycle, and cell apoptosis analyses
Cell proliferation was evaluated at the indicated time
points using the Cell Counting Kit-8 (CCK-8) Assay kit
(Dojindo Molecular Technologies Inc, Kumamoto,
Japan) according to the manufacturer’s protocol. Briefly,
cells were incubated in 10 % CCK-8 for 2 h at 37 °C and
the optical density value was then measured at 450 nm
with a microplate reader (Sunrise, Tecan, Austria). The
data are presented as the means ± SD of three independ-
ent experiments. The cell cycle distribution of BV173
and K562 cells was analysed 72 h after transfection with
either a miR-362-5p inhibitor or a negative control. Cells
were collected after washing twice with PBS, fixing in
75 % cold ethanol for 12 h, staining with propidium iod-
ide (PI), and they were then evaluated by flow cytometry
(BD Biosciences, Bedford, MD, USA). Similarly, cell
apoptosis was analysed in BV173 and K562 cells by flow
cytometry using the Annexin V-FITC/PI Apoptosis De-
tection Kit (BD Biosciences) 48 h after transfection with
either an miR-362-5p inhibitor or a negative control.
Migration and invasion, soft-agar colony formation assay
Migration and invasion assays were performed with
using Transwell Boyden Chamber (Corning, Cambridge,
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MA, USA). For the migration assay, cells were seeded
into the upper compartment. For the invasion assay,
cells were seeded into the upper chamber with an insert
that was precoated with Matrigel (BD Biosciences). The
chambers were then inserted into a 24-well culture plate
and filled with RPMI-1640 medium containing 10 %
FBS. After 12 h, the cells remaining on the upper surface
of the membranes were scraped off, whereas, the cells
located on the lower surface were fixed, stained with
0.1 % crystal violet, imaged, and counted under a micro-
scope (Olympus, Tokyo, Japan). The same experiments
were independently repeated three times.
To perform the soft agar colony-forming assay, a 1.4-ml
base layer of agar (0.6 % agar in PRI1640 with 10 % FBS)
was solidified in a six-well flat-bottomed plate before the
addition of 1 ml of cell suspension in PRI1640 containing
3000 cells, 0.3 % agar and 10 % FBS, 24 h after transfec-
tion. The colonies were counted and imaged 12 days later.
Lentivirus-mediated suppression of miR-362-5p
The lentivirus was obtained from Genechem (Shanghai,
China). For the control or miR-362-5p inhibition group,
a sequence encoding a miR-362-5p negative control or
its specific inhibitor was cloned into the lentiviral vector
pCDH- CMV-MCS-EF1-coGFP. K562 cells(1 × 106) were
infected with 1 × 107 lentivirus transducing units in the
presence of 10 μg/ml polybrene (Sigma-Aldrich).
Animal experiments
All animal experiments were conducted with approval
from the Animal Care and Use Committee of Anhui
Medical University, China. Six-week-old female BALB/c
nude mice (HFK, Beijing, China) were used to analyse
tumourigenicity. 1 × 107 K562 cells infected with either a
miR-362-5p-inhibitor or the control lentivirus were sub-
cutaneously inoculated into the left subaxillary region of
nude mice. The tumours were measured every 3 days,
and tumour volumes were estimated using the following
formula: 1/2(length × width2). The mice were sacrificed
21 days after cell injection, and then the final tumour
weights and volumes were determined.
Western blotting and immunohistochemical analyses
For western blotting, cultured cells and peripheral blood
specimens were lysed in RIPA buffer supplemented with
complete protease inhibitor (Roche, Mannheim,
Germany). Aliquots (100 μg) of total protein extracts
were resolved on 12 % SDS-PAGE gels and transferred
to PVDF membranes. The membranes were then incu-
bated with antibodies against GADD45α (1:1000; Cell
Signaling Technology, Boston, USA), JNK1/2 (1:1000;
Cell Signaling Technology), phosphor-JNK1/2 (1:500; Cell
Signaling Technology), p38 (1:1000; Cell Signaling Tech-
nology), phosphor-p38 (1:500; Cell Signaling Technology),
or β-actin (1:10000; Santa Cruz Biotechnology, Santa
Cruz, CA). Subsequently, the membranes were incubated
with specific HRP-conjugated secondary antibodies
(1:1000; Sigma-Aldrich, St Louis, MO, USA). Signals were
detected using the enhanced chemiluminescence western
blotting system (ComWin Biotech, Beijing, China).
For immunohistochemical analyses, tissues were har-
vested from xenograft model, fixed in 3 % formaldehyde
at room temperature for 12 h, followed by fixation in
methanol at -20 °C for 10 min. The samples were em-
bedded and sectioned according to standard procedure.
The sections were incubated with anti-GADD45α (Cell
Signaling Technology) at 4 °C overnight, followed by in-
cubation with an HRP-conjugated secondary antibody
(Sigma-Aldrich). Image acquisition was performed on a
DM100 Leica Photosystem (Leica, Milan, Italy).
Luciferase reporter assay
The 3’ untranslated region (3’-UTR) of human GADD45α
was PCR-amplified from human genomic DNA and cloned
into the XhoI/NotI sites of psi-CHECK2 (Promega,
Madison, WI, USA) to generate the 3’-UTR wild-type re-
porter plasmid. A mutation of the GADD45α 3’-UTR se-
quence was performed using a Quick-change Site-Directed
Mutagenesis kit (Stratagene, LaJolla, CA). 293 T, BV173,
and K562 cells (1 × 105 cells/well) were transfected with
250 pg/μl psi-CHECK2 vector 50 nM miR-362-5p mimic
and/or inhibitor, and control oligonucleotides. The cells
were harvested 48 h after transfection and analysed for
luciferase signals using Dual Luciferase Assays Kits
(Promega) on a glomax-20/20 Luminometer (Promega).
Statistical analysis
The data are expressed as the mean ± SD of at least three
independent experiments. Differences were analysed using
Student’s t-test (two-tailed). A P value of 0.05 or less was
considered statistically significant.
Additional files
Additional file 1: MiR-362-5p expression level in imatinib-resistant
K562 cells is up-regulated. qRT-PCR analysis of miR-362-5p in imatinib-
sensitive K562 cells (K562) and imatinib-resistant K562 cells (K562IR). U6
snRNA was used as an internal control. *P < 0.05. (DOC 56 kb)
Additional file 2: MiR-362-5p promoted CML cell growth in vitro.
(A) qRT-PCR analysis of miR-362-5p in the BV173 and K562 cell lines transfected
either with a miR-362-5p mimic (mimic) or a miR-362-5p mimic control
(mimic-ctrl). U6snRNA was used as an internal control. (B) Proliferation of
BV173 and K562 cells was assessed using the CCK-8 assay; cells were treated
either with a mimic or a mimic-ctrl. **P < 0.01. (DOC 85 kb)
Additional file 3: MiR-362-5p expression altered the proliferation of
CML cells in dose-dependent manner. (A) Relative cell growth rate of
BV173 and K562 cells after transfected with miR-362-5p mimics for 48 h
in different concentration. (B) Relative cell survival rate of BV173 and K562
cells after transfected with miR-362-5p inhibitor for 48 h in different
concentration. Data in histograms are represented as mean ± SD. T test,
*P < 0.05. **P < 0.01 compared with the control. mc: miR-362-5p mimic
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control; 10 m, 25 m, 50 m, 100 m:10, 25, 50, 100 mM miR-362-5p mimic;
ic: miR-362-5p inhibitor control; 10i, 25i, 50i, 100i:10, 25, 50, 100 mM
miR-362-5p inhibitor. (DOC 71 kb)
Additional file 4: Inhibition of miR-362-5p reduced the colony
formation ability of CML cell lines. BV173 and K562 cells were
transfected with either a miR-362-5p inhibitor (inhibitor) or a miR-362-5p
inhibitor control (inhibitor-ctrl). (A&B) Representative micrographs (left) and
(B) quantification (right) of colony formation determined with an in vitro
anchorage-independent growth assay. Colonies > 0.1 mm were scored.
**P < 0.01. (DOC 110 kb)
Additional file 5: Relative expression of miR-362-5p in Lv- miR-362-
5p-inhibitor expressing K562 cells. qRT-PCR analysis of miR-362-5p in
Lv-miR-362-5p-inhibitor (Lv-inhibitor) or Lv-ctrl expressing K562 cells. The
expression levels of miR-362-5p were normalized to that of the U6 snRNA
control. **P < 0.01. (DOC 58 kb)
Additional file 6: MiR-362-5p was reduced in lv-miR-362-5p-inhibitor
tumors compare with lv-ctrl tumors. qRT-PCR analysis of miR-362-5p in
Lv-miR-362-5p-inhibitor or Lv-ctrl expressing xenograft tumors. *P < 0.05.
(DOC 50 kb)
Additional file 7: qRT-PCR analysis of miR-362-5p in 293 T cell lines
transfected with a miR-362-5p mimic (mimic) or a mimic control
(mimic-ctrl). **P < 0.01. (DOC 44 kb)
Additional file 8: Table S1. Clinical and cytogenetic characteristic of
CML patients. Table S2. The sequences of primes used for qRT-PCR analysis.
Table S3. The sequences of the mimic, inhibitor and si-RNA used for
transient transfection. (DOC 74 kb)
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